175POverall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS). (25th November 2018) - Shitara, K; Tabernero, J; Dvorkin, M; Mansoor, W; Arkenau, H-T; Prokharau, A; Alsina, M; Ghidini, M; Faustino, C; Gorbunova, V; Zhavrid, E; Nishikawa, K; et al.